Toll-like receptors (TLRs) play a crucial role in the onset of innate immunity by distinguishing between endogenous and pathogen-associated molecular patterns. TLR2, in cooperation with TLR1 and TLR6, recognizes several microbial components such as lipoteichoic acids and lipoproteins [1] . Toll-like receptors have been broadly reported to contribute to several inflammatory chronic diseases and autoimmune diseases [2] . In this study we aim to discover new TLR2 modulating agents through computer-aided drug design.
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Based on recently identified synthetic TLR2 agonists [3] and antagonists [4] , a shape and chemical-feature based similarity search was performed against a library of 260.071 compounds provided by the National Cancer Institute (NCI) [5] . This led to several virtual hits, which were tested in vitro in a cell-based assay. Several compounds with biological activity on TLR2 signaling in general and TLR1 signaling specifically were identified.
To further optimize these biologically validated virtual hits, molecular interaction fields (MIFs) for the dimerization of TLR2 and TLR1 were developed. Featurebased MIFs allowed for the manual creation of virtual compounds that fulfill an optimized interaction pattern, which led to a 3D pharmacophore that was used for a second virtual screening to select compounds for biological testing.
